Schering-Plough, Merck End Venture | Chemical & Engineering News
Volume 86 Issue 27 | p. 11 | Concentrates
Issue Date: July 7, 2008

Schering-Plough, Merck End Venture

Department: Business

Merck & Co. and Schering-Plough have dissolved their respiratory joint venture after withdrawing their New Drug Application for a pill that combines the active ingredients in Schering-Plough's Claritin and Merck's Singulair. The decisions come two months after FDA said it would not approve the combination drug. As a result of the move, Schering-Plough will receive $105 million from Merck. The companies say the termination of the respiratory venture, which was formed in 2000, does not affect their cholesterol collaboration.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment